Vela launches new PCR test for detecting urinary tract infection

By staff writers

May 19, 2022 -- Vela Diagnostics has launched a new PCR-based test for detecting urinary tract infection pathogens and antimicrobial resistance genes.

The test, called PathoKey MP UTI ID and AMR PCR, is currently for research use only, the company said. It allows for the in vitro detection and categorization of 14 pathogens that cause urinary tract infections and 14 antimicrobial resistance genes that block five antibiotics.

The test is compatible with real-time PCR cyclers such as Rotor-Gene Q 5/6 plex platforms and the QuantStudio 5 Real-Time PCR system, according to Vela.

It also offers the option of either automated or manual workflow, Vela Diagnostics said.

Vela promotes new pooling capability for SARS-CoV-2 test
Vela Diagnostics is promoting the additional pooling capability of its ViroKey SARS-CoV-2 RT-PCR test, which received emergency use authorization (EUA)...
Vela Diagnostics adds 2 SARS-CoV-2 assays
Vela Diagnostics has added two SARS-CoV-2 assays to its portfolio: ViroKey SQ Flex SARS-CoV-2 genotyping and ViroKey SARS-CoV-2 ID reverse transcription...
FDA grants Vela EUA for SARS-CoV-2 test
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Vela Diagnostics for the manual version of its ViroKey coronavirus...
Vela's SARS-CoV-2 test cleared for Europe
Vela Diagnostics has received the CE-IVD Mark in Europe for the manual version of its reverse transcription polymerase chain reaction test for SARS-CoV-2.
Vela wins FDA clearance for HIV-1 genotyping NGS assay
Vela Diagnostics USA has garnered U.S. Food and Drug Administration (FDA) marketing approval for its Sentosa SQ HIV-1 genotyping assay, a test designed...

Copyright © 2022

Last Updated mp 5/19/2022 6:06:50 AM